Literature DB >> 26283639

A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.

M S Milak1,2, C J Proper1, S T Mulhern1, A L Parter1, L S Kegeles1,2, R T Ogden1,2,3, X Mao4, C I Rodriguez1,2, M A Oquendo1,2, R F Suckow2,5, T B Cooper2,5, J G Keilp1,2, D C Shungu2,4, J J Mann1,2,6.   

Abstract

The N-methyl-D-aspartate receptor antagonist ketamine can improve major depressive disorder (MDD) within hours. To evaluate the putative role of glutamatergic and GABAergic systems in ketamine's antidepressant action, medial prefrontal cortical (mPFC) levels of glutamate+glutamine (Glx) and γ-aminobutyric acid (GABA) were measured before, during, and after ketamine administration using proton magnetic resonance spectroscopy. Ketamine (0.5 mg kg(-1) intravenously) was administered to 11 depressed patients with MDD. Glx and GABA mPFC responses were measured as ratios relative to unsuppressed voxel tissue water (W) successfully in 8/11 patients. Ten of 11 patients remitted (50% reduction in 24-item Hamilton Depression Rating Scale and total score ⩽10) within 230 min of commencing ketamine. mPFC Glx/W and GABA/W peaked at 37.8%±7.5% and 38.0%±9.1% above baseline in ~26 min. Mean areas under the curve for Glx/W (P=0.025) and GABA/W (P=0.005) increased and correlated (r=0.796; P=0.018). Clinical improvement correlated with 90-min norketamine concentration (df=6, r=-0.78, P=0.023), but no other measures.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26283639      PMCID: PMC4758914          DOI: 10.1038/mp.2015.83

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  85 in total

1.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

Review 2.  Ketamine, magnesium and major depression--from pharmacology to pathophysiology and back.

Authors:  Harald Murck
Journal:  J Psychiatr Res       Date:  2013-03-26       Impact factor: 4.791

Review 3.  Magnesium and depression: a systematic review.

Authors:  Marie-Laure Derom; Carmen Sayón-Orea; José María Martínez-Ortega; Miguel A Martínez-González
Journal:  Nutr Neurosci       Date:  2012-12-06       Impact factor: 4.994

4.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382

5.  Sex differences in the antidepressant-like effects of ketamine.

Authors:  Nicole Carrier; Mohamed Kabbaj
Journal:  Neuropharmacology       Date:  2013-01-19       Impact factor: 5.250

Review 6.  Ketamine administration in depressive disorders: a systematic review and meta-analysis.

Authors:  Guillaume Fond; Anderson Loundou; Corentin Rabu; Alexandra Macgregor; Christophe Lançon; Marie Brittner; Jean-Arthur Micoulaud-Franchi; Raphaelle Richieri; Philippe Courtet; Mocrane Abbar; Matthieu Roger; Marion Leboyer; Laurent Boyer
Journal:  Psychopharmacology (Berl)       Date:  2014-07-20       Impact factor: 4.530

7.  Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.

Authors:  Allison C Nugent; Nancy Diazgranados; Paul J Carlson; Lobna Ibrahim; David A Luckenbaugh; Nancy Brutsche; Peter Herscovitch; Wayne C Drevets; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2013-09-18       Impact factor: 6.744

Review 8.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes.

Authors:  A McGirr; M T Berlim; D J Bond; M P Fleck; L N Yatham; R W Lam
Journal:  Psychol Med       Date:  2014-07-10       Impact factor: 7.723

9.  Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.

Authors:  Paulo R Shiroma; Brian Johns; Michael Kuskowski; Joseph Wels; Paul Thuras; C Sophia Albott; Kelvin O Lim
Journal:  J Affect Disord       Date:  2013-10-29       Impact factor: 4.839

10.  Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression.

Authors:  Maura Boldrini; Adrienne N Santiago; René Hen; Andrew J Dwork; Gorazd B Rosoklija; Hadassah Tamir; Victoria Arango; J John Mann
Journal:  Neuropsychopharmacology       Date:  2013-01-07       Impact factor: 7.853

View more
  52 in total

1.  Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy.

Authors:  Marc J Dubin; Xiangling Mao; Samprit Banerjee; Zachary Goodman; Kyle A B Lapidus; Guoxin Kang; Conor Liston; Dikoma C Shungu
Journal:  J Psychiatry Neurosci       Date:  2016-04       Impact factor: 6.186

2.  Network-Guided Transcranial Magnetic Stimulation for Depression.

Authors:  Marc J Dubin; Conor Liston; Michael A Avissar; Irena Ilieva; Faith M Gunning
Journal:  Curr Behav Neurosci Rep       Date:  2017-02-07

Review 3.  Imaging TMS: antidepressant mechanisms and treatment optimization.

Authors:  Marc Dubin
Journal:  Int Rev Psychiatry       Date:  2017-02-15

Review 4.  Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

Authors:  Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

5.  Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.

Authors:  Meng Li; Liliana Ramona Demenescu; Lejla Colic; Coraline Danielle Metzger; Hans-Jochen Heinze; Johann Steiner; Oliver Speck; Anna Fejtova; Giacomo Salvadore; Martin Walter
Journal:  Neuropsychopharmacology       Date:  2016-09-08       Impact factor: 7.853

6.  Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Authors:  Jerome H Taylor; Angeli Landeros-Weisenberger; Catherine Coughlin; Jilian Mulqueen; Jessica A Johnson; Daniel Gabriel; Margot O Reed; Ewgeni Jakubovski; Michael H Bloch
Journal:  Neuropsychopharmacology       Date:  2017-08-29       Impact factor: 7.853

7.  Dorsolateral prefrontal γ-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy

Authors:  Jennifer G. Levitt; Guldamla Kalender; Joseph O’Neill; Joel P. Diaz; Ian A. Cook; Nathaniel Ginder; David Krantz; Michael J. Minzenberg; Nikita Vince-Cruz; Lydia D. Nguyen; Jeffry R. Alger; Andrew F. Leuchter
Journal:  J Psychiatry Neurosci       Date:  2019-11-01       Impact factor: 6.186

8.  Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.

Authors:  Meng Li; Marie Woelfer; Lejla Colic; Adam Safron; Catie Chang; Hans-Jochen Heinze; Oliver Speck; Helen S Mayberg; Bharat B Biswal; Giacomo Salvadore; Anna Fejtova; Martin Walter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10-23       Impact factor: 5.270

Review 9.  Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.

Authors:  Marc S Lener; Mark J Niciu; Elizabeth D Ballard; Minkyung Park; Lawrence T Park; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2016-05-12       Impact factor: 13.382

Review 10.  KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

Authors:  Chadi G Abdallah; Thomas G Adams; Benjamin Kelmendi; Irina Esterlis; Gerard Sanacora; John H Krystal
Journal:  Depress Anxiety       Date:  2016-04-06       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.